hrp0092fc6.2 | Bone, Growth Plate and Mineral Metabolism Session 2 | ESPE2019

Zone Wise Cell Separation Methods Comparison, Based on Relative Expression of Specific Growth Plate Markers in a Pig Model

Javanmardi Alireza , Raimann Adalbert , Egerbacher Monika , Sagmeister Susane , Gleiss Andreas , Haeusler Gabriele

Introduction: Longitudinal skeletal growth is achieved by enchondral ossification in epiphyseal growth plates (GP) of long bones and vertebrae. These highly organized cartilaginous tissues contain chondrocytes of all differentiational stages classified in three distinct zones named resting, proliferative and hypertrophic. Separated analysis of individual zones is essential in basic GP research thus efficiency of different zonal separation methods confers high ...

hrp0097p1-121 | Growth and Syndromes | ESPE2023

First year reponse to growth hormone (GH) therapy is related to long term outcome in GH deficiency (GHD) but not in children born small for gestational age (SGA)

Hartmann Gabriele , Ertl Diana-Alexandra , Raimann Adalbert , Haufler Florentina , Gleiss Andreas , Ashraf Soliman , Mai Alqubasi , Tawa Olukade , Hamdy Ali , Mohamed Alturk , Nada Alaaraj , Noor Hamed , Shayma Ahmed

In the history of biosynthetic GH, first prediction models on long term outcome of therapy were based on large multinational cohorts of various growth disorders and have concentrated on GH dose. In this study we analyzed the 1st year and final height (FH) data in a large single center cohort (center of expertise for rare growth disorders) and compared patient outcome and predictions in GHD and SGA. Our aim was to predict treatment outcome using simple previously suggested para...

hrp0095fc2.6 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Pseudohypoparathyroidism Type 1A (PHP1A): Growth patterns under growth hormone therapy for short stature

Ertl Diana-Alexandra , Mantovani Giovanna , Perez de Nanclares Guiomar , Gleiss Andreas , Hanna Patrick , Marta Elli Francesca , Pereda Arrate , Rothenbuhler Anya , Audrain Christelle , Berkenou Jugurtha , Linglart Agnes

Background: Pseudohypoparathyroidism 1A, newly classified as inactivating PTH/PTHrP signaling disorder type 2 (iPPSD2), is defined by resistance to parathyroid hormone, short stature and early-onset obesity. Short stature is caused by skeletal dysplasia and additionally, in some cases, also by the coexistence of growth hormone deficiency, as other hormonal resistances might be present (e.g. thyroid-stimulating hormone, growth hormone releasing hormone (GHRH), ...

hrp0092p1-76 | GH and IGFs | ESPE2019

The Diagnostic Value of Serum Acid-labile Subunit (ALS) Alone and in Combination with IGF-1 and IGFBP-3 in the Diagnosis of Idiopathic Growth Hormone Deficiency (iGHD)

Chen Jiajia , Ertl Diana- Alexandra , Andreas Gleiss , Janu Dominik , Sagmeister Susanne , Raimann Adalbe , Gong ChunXiu , Haeusler Gabriele

Background: The acid-labile subunit (ALS) is the crucial third player in the tertiary complex for its function of prolonging the half-life of the IGF1-IGFBP3 binary complexes. IGF1 and IGFBP3 are routinely determined during the diagnostic work-up for growth hormone deficiency (GHD). The aim of the study is to evaluate the relevance of serum ALS as an additional biomarker, alone or in combination with IGF1 and IGFBP3, in the diagnosis of GHD.<p class="abste...

hrp0084p2-475 | Growth | ESPE2015

Growth Hormone Deficiency and Pituitary Dysgenesis in a Girl with Microdeletion 2q31.1

Hammer Elke , Busche Andreas , Gillessen-Kaesbach Gabriele

Background: Microdeletions of the chromosomal region 2q31.1 are rare. Growth retardation is reported in the majority of these patients, but information about growth hormone status is not given in the literature. Other typical features in 2q31.1 deletion syndrome are developmental delay, limb abnormalities, short palpebral fissures, heart defects, among others.Objective and hypotheses: A 12 year old girl presented at the age of 7 years with severe growth ...

hrp0094p2-147 | Diabetes and insulin | ESPE2021

Thrombocytopaenia induced by diazoxide treatment in a toddler with Hyperinsulinism-Hyperammonemia syndrome: a rare side-effect

Bisbinas Vasiliki , Giannopoulos Andreas , Karabouta Zacharoula ,

Introduction: Diazoxide is the first-line drug for Hyperinsulinemia-Hyperammonemia (HI/HA) syndrome, a disease due to a mutation in the glutamate dehydrogenase-1 (GLUD1) gene.Diazoxide, an opener of the pancreatic β-cells KATP-channels reducing insulin release, is uncommonly associated with thrombocytopaenia.Aim: We describe a toddler with HI/HA syndrome who developed thrombocytopaenia on diazoxide treatment.<p ...

hrp0092p3-53 | Diabetes and Insulin | ESPE2019

A Case of Congenital Hyperinsulinism due to ABCC8 Mutation: A Challenge to Diagnosis, Management, and Treatment

Karabouta Zacharoula , Rouga Elena , Nakouti Eleni , Bisbinas Vasiliki , Giannopoulos Andreas

Introduction: Congenital hyperinsulinism(CHI) is a rare complex disorder of hypoglycaemia attributable to inappropriate and dysregulated insulin secretion from the pancreas with an incidence of 1:50 000(1:2500 in consanguineous populations). Genetics involves defects mainly in the KATP channel genes ABCC8 and KCNJ11.Aim: We describe a male infant, presented with refractory hypoglycaemia the first week of life.<p clas...

hrp0092p3-184 | Multisystem Endocrine Disorders | ESPE2019

Eosinophilic Ascites: A Rare Complication of Autoimmune Polyendocrinopathy

Moudiou Tatiani , Tsikopoulos Georgios , Bisbinas Vasiliki , Giannopoulos Andreas , Karabouta Zacharoula

Introduction: Autoimmune polyendocrinopathy syndrome (APS) is an inherited rare autosomal recessive disorder caused by mutations of the AIRE (autoimmune regulator) gene with organ-specific autoimmune destruction of several, mostly endocrine. APS patients may develop autoimmune enteropathies and other intestinal dysfunctions.Aim: We describe a case of eosinophilic ascites in a nine-year-old girl with APS.<p c...

hrp0089p1-p164 | Growth &amp; Syndromes P1 | ESPE2018

Changing Patterns of Growth in Prader-Willi Syndrome

Irene Neophytou Georgia , Frixou Mikaela , Guftar Shaikh M. , Kyriakou Andreas

Introduction/Aim: Children with Prader-Willi syndrome (PWS) show alterations in infantile, childhood and pubertal growth. Growth Hormone (GH) therapy is recommended due to reported improvements in height velocity (HV) and body composition. The aim was to describe the patterns of growth in PWS and the influence of both changes in clinical practice and GH therapy.Methods: Height SDS (HSDS), BMISDS and HVSDS of children attending a dedicated PWS clinic, 200...

hrp0086p1-p22 | Adrenal P1 | ESPE2016

An Assessment of the Hypothalamic–Pituitary–Adrenal Axis in Children with Prader–Willi Syndrome

Kyriakou Andreas , Lewis Sarah , Coveney John , Roche Edna F.

Background: In children with Prader–Willi Syndrome (PWS), hypothalamic dysfunction plays a key role in the development of aberrant energy regulation, sleep-related breathing disorders, hypogonadism and impaired linear growth. Dysfunction of the hypothalamic–pituitary–adrenal (HPA) axis may contribute to the high incidence of sudden death. The prevalence and the extent of the dysfunction of HPA axis remain unclear.Method: Thirty-one (10M/21...